Report for: Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of&nbsp;its&nbsp;efficacy and safety

Title	Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety
Published in	Drug Design, Development and Therapy, November 2014
DOI	10.2147/dddt.s73428
Pubmed ID	25473268
Authors	Xingguo Zhang, Zhihai Yang, Xingguang Liang, Kuifen Ma, Dongsheng Hong, Shuyin Han
Abstract	Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has not been evaluated, and the overall remission of AoSD with anakinra treatment has not been well defined.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
United States	4	40%
Spain	2	20%
United Kingdom	1	10%
Unknown	3	30%

Demographic breakdown

Type	Count	As %
Members of the public	8	80%
Practitioners (doctors, other healthcare professionals)	2	20%

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Unknown	35	100%

Demographic breakdown

Readers by professional status	Count	As %
Researcher	6	17%
Student > Postgraduate	5	14%
Student > Master	4	11%
Student > Bachelor	3	9%
Student > Ph. D. Student	3	9%
Other	6	17%
Unknown	8	23%

Readers by discipline	Count	As %
Medicine and Dentistry	12	34%
Pharmacology, Toxicology and Pharmaceutical Science	4	11%
Agricultural and Biological Sciences	3	9%
Neuroscience	3	9%
Immunology and Microbiology	1	3%
Other	1	3%
Unknown	11	31%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2022.

All research outputs

#3,325,214

of 23,114,117 outputs

Outputs from Drug Design, Development and Therapy

#200

of 2,109 outputs

Outputs of similar age

#40,481

of 261,438 outputs

Outputs of similar age from Drug Design, Development and Therapy

#11

of 54 outputs

Altmetric has tracked 23,114,117 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 2,109 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 90% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,438 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.

We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.

Dove Medical Press

Article Metrics

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context